Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Curative treatment of peritoneal carcinomatosis of colorectal origin

Zoetmulder, F. A.N. ; Smeenk, R. M. and Verwaal, V. J. LU (2005) In European Journal of Cancer, Supplement 3(3). p.411-413
Abstract

Up to 8% of all patients with colorectal cancer have peritoneal carcinomatosis (PC) as the only site of disease at some point in time. Traditional treatment by limited palliative surgery and systemic chemotherapy has poor results with few patients surviving longer than 3 years. Complete cytoreductive surgery combined with Hyperthermic Intra Peritoneal Chemotherapy (HIPEC), using Mitomycin C, followed by adjuvant chemotherapy has been extensively tested. Both in Phase II and in randomised phase III trials this combination therapy has shown superior results, with a median survival of 2 years and a 5-year disease-free survival of 20-25%.

Please use this url to cite or link to this publication:
author
; and
publishing date
type
Contribution to journal
publication status
published
in
European Journal of Cancer, Supplement
volume
3
issue
3
pages
3 pages
publisher
Elsevier
external identifiers
  • scopus:27344454629
ISSN
1359-6349
DOI
10.1016/S1359-6349(05)80303-9
language
English
LU publication?
no
id
52d064e3-de40-4e1f-9bf2-67f5df365277
date added to LUP
2022-04-12 11:09:52
date last changed
2022-04-12 17:01:01
@article{52d064e3-de40-4e1f-9bf2-67f5df365277,
  abstract     = {{<p>Up to 8% of all patients with colorectal cancer have peritoneal carcinomatosis (PC) as the only site of disease at some point in time. Traditional treatment by limited palliative surgery and systemic chemotherapy has poor results with few patients surviving longer than 3 years. Complete cytoreductive surgery combined with Hyperthermic Intra Peritoneal Chemotherapy (HIPEC), using Mitomycin C, followed by adjuvant chemotherapy has been extensively tested. Both in Phase II and in randomised phase III trials this combination therapy has shown superior results, with a median survival of 2 years and a 5-year disease-free survival of 20-25%.</p>}},
  author       = {{Zoetmulder, F. A.N. and Smeenk, R. M. and Verwaal, V. J.}},
  issn         = {{1359-6349}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{411--413}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer, Supplement}},
  title        = {{Curative treatment of peritoneal carcinomatosis of colorectal origin}},
  url          = {{http://dx.doi.org/10.1016/S1359-6349(05)80303-9}},
  doi          = {{10.1016/S1359-6349(05)80303-9}},
  volume       = {{3}},
  year         = {{2005}},
}